FLUOXETINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Fluoxetine Hydrochloride patents expire, and what generic alternatives are available?
Fluoxetine Hydrochloride is a drug marketed by Barr, Dr Reddys Labs Ltd, Accord Hlthcare, Alembic Pharms Ltd, Ani Pharms, Aurobindo Pharma, Cadila Pharms Ltd, Carlsbad, Chartwell Rx, Cr Double Crane, Heritage, Ivax Sub Teva Pharms, Landela Pharm, Marksans Pharma, Micro Labs, Natco Pharma Usa, Pharmobedient, Regcon Holdings, Sandoz, Sciegen Pharms, Senores Pharms, Specgx Llc, Strides Pharma Intl, Sun Pharm Inds Ltd, Teva, Teva Pharms Usa, Actavis Mid Atlantic, Bajaj, Chartwell Molecular, Lannett Co Inc, Novitium Pharma, Pharm Assoc, Pharmobedient Cnsltg, Solis Pharms, Upsher Smith Labs, Alembic, Aurobindo Pharma Ltd, Dr Reddys, Fosun Pharma, G And W Labs Inc, Inventia Hlthcare, Lupin, Ph Health, Rising, Somerset Theraps Llc, Strides Pharma, Torrent, and Twi Pharms. and is included in sixty-seven NDAs.
The generic ingredient in FLUOXETINE HYDROCHLORIDE is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fluoxetine Hydrochloride
A generic version of FLUOXETINE HYDROCHLORIDE was approved as fluoxetine hydrochloride by MARKSANS PHARMA on August 2nd, 2001.
